(Boursier.com) — Intrasense specialist in medical imaging software solutions and designer of Myrian, and Guerbet announce that the Myrian 2.12 platform has obtained the CE certificate under MDR, integrating the prostate AI developed by Guerbet, the Veolity LungCAD AI developed by Mevis and the Icobrain AI developed by Icometrix.
This market launch is a major step in the joint development plan of the two companies and the realization of their growth ambition. Thus, Myrian successfully obtained its CE certification for this new version 2.12 on April 5, 2024, allowing its marketing in Europe. The integration of AI algorithms within Myrian, a platform recognized for its ease of use and its broad functional spectrum, offers radiologists easier interpretation of medical imaging exams thanks to cutting-edge technologies directly available in their workflow.
The marking of this new version of the Myrian platform allows Intrasense to accelerate its expansion strategy in Europe, taking advantage in particular of the collaboration with Guerbet to increase its international visibility and target new markets. “The certification of our Myrian 2.12 solution represents a crucial step in our innovation trajectory. This validation marks our continued commitment to technological excellence and also constitutes an opportunity to accelerate our growth. The new AI algorithms, notably developed by our partner Guerbet, allow us to strengthen the added value of our software solutions and maximize the relevance of our offer on the markets”, indicates Nicolas Reymond, Managing Director of Intrasense.
New commercial brand
Guerbet announces the launch of its DUOnco commercial brand, which will bring together all of the Group’s artificial intelligence algorithms. Thus, the algorithms of the DUOnco brand will be integrated into the Intrasense product portfolio and can, under cover of regulatory certifications, also be marketed in stand-alone mode to partners, by Intrasense and by Guerbet. In addition to AI for prostate cancer, Guerbet is also working on several algorithms dedicated to detecting cancer lesions in the liver, pancreas and bones.
Quoting…
The integration of Guerbet’s prostate AI into Intrasense solutions constitutes a major step. Perfectly integrated into tools dedicated to clinical routine, AI facilitates diagnosis and therapeutic decision-making. AI automatically segments the prostate and provides its volume, simplifying the calculation of PSA (prostate specific antigen) density.
This collaboration allows Intrasense to enrich its solutions with cutting-edge clinical tools, thus offering healthcare professionals valuable tools to gain diagnostic performance in the analysis of prostate MRI.